HCPCS G0476: HPV High-Risk Nucleic Acid Detection for Cervical Screening

HCPCS Level II code G0476 identifies laboratory testing for high-risk human papillomavirus (HPV) nucleic acid detection performed in conjunction with a Pap test for cervical cancer screening. This molecular diagnostic code is nationally important because high-risk HPV testing is integral to cervical cancer prevention strategies and impacts screening workflows, laboratory utilization, and payer coverage policies across commercial and public programs. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of the clinical context for HPV high-risk nucleic acid testing, typical sites of service, and where this test fits into guideline-directed cervical cancer screening. The publication summarizes coverage considerations and common billing practices, common modifiers associated with laboratory and professional components, and benchmarks for utilization and reimbursement where available. It also highlights policy and coding nuances relevant to laboratories, clinicians who order co-testing with Pap tests, and revenue cycle teams managing claims for molecular diagnostics.

Billing Code Overview

HCPCS Level II code G0476 describes infectious agent detection by nucleic acid (DNA or RNA) for high-risk human papillomavirus (HPV) types used for cervical cancer screening. The service specifies detection of high-risk HPV genotypes (for example, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and must be performed in addition to a Pap test.

Service type: Laboratory molecular diagnostic test (HPV high-risk nucleic acid detection)
Typical site of service: Clinical or hospital laboratory; specimen collection typically occurs in outpatient gynecology or primary care settings where cervical cancer screening is performed.

Clinical Context

A 34-year-old woman presents to a gynecology clinic for routine cervical cancer screening. During the visit a clinician performs a pelvic exam and collects cervical cytology (Pap test). Per current guidance for co-testing, a separate specimen is collected or processed for high-risk human papillomavirus testing using a nucleic acid amplification method to detect HPV DNA/RNA for high-risk types (for example, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68). The service G0476 is reported when the HPV test is performed in addition to the Pap test. Typical workflow: patient registration and insurance verification; informed consent for screening; specimen collection (cytology and HPV specimen as required); labeling and ordering of HPV molecular test; laboratory processing using nucleic acid detection methods; result entry into the electronic health record and communication of results to the patient. Typical site of service is an outpatient ambulatory clinic or physician office and the testing is performed by an accredited clinical laboratory. Common clinical scenarios include routine screening in women aged ≥30 years as part of Pap and HPV co-testing, follow-up of equivocal cytology (e.g., atypical squamous cells of undetermined significance), or surveillance after treatment for cervical dysplasia.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When billing separately for physician's interpretation of the test if the laboratory reports technical component separately.
`52`	Reduced services	If the HPV test is partially performed or limited relative to full-service circumstances.
`53`	Discontinued procedure	When testing specimen collection is started but discontinued due to patient-related reasons.
`59`	Distinct procedural service	When another separately identifiable service is furnished on the same day and not typically bundled with the HPV test.
`62`	Two surgeons	Rarely applicable; when two qualified professionals share responsibility for care related to the service.
`76`	Repeat procedure by same physician	If the HPV test is repeated later the same day by the same provider (note: `76` not in provided list; not applicable).
`77`	Repeat procedure by another physician	If repeated by a different physician the same day (note: `77` not in provided list; not applicable).
`73`	Discontinued outpatient hospital/ambulatory surgery before anesthesia	If specimen collection planned but discontinued before significant services (rare for this test).
`78`	Return to OR for a related procedure following initial procedure (rare)	Not typically applicable to HPV testing; included when clinically relevant.
`80`	Assistant surgeon	If an assistant surgeon is billed for a related surgical procedure on same day (not typical for screening).

Taxonomy Code	Specialty	Notes
`207Q00000X`	Obstetrics & Gynecology	Primary specialty performing cervical screening and ordering HPV testing.
`208D00000X`	Pathology	Pathologists may oversee laboratory testing and interpretation of molecular assays.
`261QM0800X`	Clinical Laboratory Director	Laboratory directors and medical technologists manage nucleic acid testing protocols.
`163W00000X`	Family Medicine	Family practitioners providing preventive screening in primary care settings.
`207L00000X`	Gynecologic Oncology	May order HPV testing in surveillance of cervical neoplasia.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z11.51`	Encounter for screening for human papillomavirus (HPV)	Primary screening encounter when HPV testing is performed as part of preventive care.
`Z01.411`	Encounter for gynecological examination (general) (routine) with abnormal findings	Used when routine exam with screening leads to additional HPV testing or follow-up.
`R87.610`	Cytologic evidence of high risk HPV	Describes cytology results indicating HPV-associated changes prompting molecular testing.
`N87.9`	Dysplasia of cervix uteri, unspecified	Indicates cervical dysplasia that may be monitored or evaluated with HPV testing.
`Z12.4`	Encounter for screening for malignant neoplasm of cervix	General cervical cancer screening code used when performing Pap and HPV co-testing.
`R87.619`	Cytologic evidence of HPV, unspecified	Reflects cytology findings associated with HPV infection relevant to ordering HPV tests.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`88142`	Cytopathology, cervical or vaginal (Pap) screening; automated system, without manual review	Automated Pap testing frequently performed as the cytology component when co-testing with HPV.
`88141`	Cytopathology, cervical or vaginal (Pap) screening; manual screening and rescreening, by physician or other qualified health care professional	Manual review option for Pap tests performed alongside HPV testing.
`87621`	Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high-risk types, amplified probe technique	Alternative CPT molecular test code representing high-risk HPV detection; may be reported by some labs instead of an HCPCS code.
`G0123`	Colposcopy of the cervix including upper/adjacent vagina with biopsy(s)	Performed when abnormal cytology or positive high-risk HPV result prompts diagnostic evaluation.
`57454`	Colposcopy of the cervix including upper/adjacent vagina; with conization, loop electrode (LEEP)	Therapeutic/diagnostic procedure that may follow positive screening and biopsy-confirmed high-grade lesions.

OpenPayer

Summary & Overview